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Figure 1. OP1 activates canonical (P-Smad 1/5/8 signaling in A) healthy
and B) OA meniscus cells. C) P-Smad 1/5/8 densitometry, normalized to b-
actin, relative to unstimulated controls (mean þ/- SD).
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surgery (n¼4 in each group) were collected for morphological analysis.
Results: 1) We did not ﬁnd the initiation and acceleration of articular
cartilage degeneration by the genetic inactivation of Tgfbr2 in knee
joints of mice at the age of 9 months or older. We also did not ﬁnd
hypertrophic chondrocytes in the articular cartilage of the mice. 2) We
found that intra-articular injection of neutralizing TGF-b1 antibody into
the knee joints of Col11a1þ/- mice delayed articular cartilage degen-
eration approximately 3 months, compared to that in Col11a1þ/- mice
without the injection of the antibody. It takes about 15 months for
Col11a1þ/- mice to form OA knee joints. 3) We found that treatment
with Losartan delayed articular cartilage degeneration, induced by
DMM, compared to that in control littermates. 4) We found that
removal of Tgfbr2 in articular cartilage of knee joints delayed articular
cartilage degeneration, induced by DMM, at least 6 weeks, compared to
that in wild-type littermates. It takes about 16 weeks for mice with
DMM to develop OA knee joints.
Conclusion: Inhibition of Tgf-b1 signaling attenuated articular cartilage
degeneration in mature knee joints of mouse models of OA. Therefore,
inhibition activity of TGF-b1, not application of TGF-b1, may be con-
sidered in treatment of OA in mature joints.
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EFFECTS OF OSTEOARTHRITIS ON MENISCUS CELL RESPONSE TO
OSTEOGENIC PROTEIN 1
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Forest Univ., Winston Salem, NC, USA; zRush Univ., Chicago, IL, USA
Purpose: Degenerative meniscus injuries are highly prevalent in aged
individuals, increasing the risk and rate of total joint OA onset. Ideally,
therapies should incite anabolic matrix production and prevent total
joint tissue OA progression. However, anabolic resistance occurs during
articular cartilage aging and OA. It is thought to contribute to the risk of
OA progression due to insufﬁcient repair of normal tissue microtrauma.
Anabolic insensitivity also contributes to net tissue breakdown during
OA due to decreased tissue synthesis. Mechanisms of anabolic insen-
sitivity have not been described for meniscus tissue. The objective of
this study was to characterize normal and OA meniscus cell response to
the anabolic growth factor, Osteogenic Protein 1 (OP1/BMP7), and
examine mechanisms of anabolic resistance to OP1 during OA.
Methods: Normal human tissue was obtained through NDRI or Gift of
Hope Tissue and Organ Donor Network. Osteoarthritic tissues were
obtained as total knee arthroplasty surgical waste under IRB approval.
Normal meniscus was grade 2 or less by ICRS scores. Primary meniscus
cells were grown as high density monolayer cultures, changed to serum
free media upon reaching conﬂuence, and treated with OP1 (100 ng/
mL) or comparisons of IL1b (10 ng/mL), TGFb (10 ng/mL), GDF5 (100 ng/
mL), or IGF1 (100 ng/mL). Expression of ECM components and MMPs
was determined by RT-qPCR. Total lysates were analyzed by immuno-
blotting and evaluated using antibodies against activating phosphor-
ylations or total proteins for Smads (1/5/8, 2), MAPKs (ERK, p38), and
AKT. Band intensity was measured by ImageJ densitometry, normalized
for background and total protein, and expressed relative to unstimu-
lated samples.
Results: By RT-qPCR, OP1 stimulation increased aggrecan and collagen
type II (COL2A1) mRNA and decreased MMP-13 mRNA in all samples,
however OA meniscus cells showed reduced responses compared to
healthy cells. Normal meniscus cells separated from inner and outer
meniscus regions displayed similar mRNA levels upon OP1 stimulation,
suggesting the decreased response of OA cells to OP1 was due to disease
state, not loss of tissue region (data not shown). To identify potential
mechanisms of anabolic insensitivity, we evaluated signaling time
courses by immunoblot. Normal (n¼2) and OA (n¼3) meniscus cells,
stimulated with OP1, displayed activation of canonical BMP signaling,
evidenced by Smad1/5/8 phosphorylation (P-Smad1/5/8), while non-
canonical MAPK or AKT signaling was not observed (Figure 1A&B).
Maximum P-Smad1/5/8 occured at late time points (1.5 hours) with
similar kinetics between normal and OA cells. Normal cells responded
to OP1 stimulation with enhanced levels of P-Smad1/5/8 compared to
OA cells (Figure 1C). Stimulation with IL-1b or IGF1 showed limited
Smad 1/5/8 activation, while MAPK or AKT was activated, as expected.
Stimulation with TFGb resulted in both enhanced phospho-Smad 2 and
Smad 1/5/8 in normal and OA cells compared to unstimulated controls.
TFGb treatment induced higher phospho-Smad 1/5/8 levels in normal
vs. OA meniscus cells, similar to OP1 treated cells.Conclusions: OA meniscus cells are resistant to OP1 stimulated
extracellular matrix transcription compared to normal meniscus cells.
MMP expression is not induced by either normal or OA meniscus cells,
indicating that OP1 is not harmful and has potential therapeutic beneﬁt
for OA meniscus. Both normal and OA meniscus cells respond to OP1
stimulation by activating canonical BMP signaling (Smad1/5/8), but not
non-canonical signaling. Our current signaling experiments using OP1
and including TFGb suggest that meniscus anabolic resistance does not
affect kinetics of Smad activation, but inﬂuences total amount of Smad
phosphorylation. Stimulation with TFGb also resulted in differential
Smad 1/5/8 activation, suggesting that Smad signaling is a target
pathway for overcoming anabolic resistance during meniscus cell OA.
Discovering mechanisms of OA cell anabolic resistance will enhance
therapeutic targeting to overcome resistance and contribute to resto-
ration of tissue homeostasis beneﬁcial to the whole knee joint.23
EFFICACY OF CULTURE-EXPANDED MESENCHYMAL STROMAL CELLS
VERSUS CONCENTRATED BONE MARROW IN AN EXPERIMENTAL
OSTEOARTHRITIS SHEEP MODEL
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Purpose: Despite the advantages in the ﬁeld of regenerative medicine
for cartilage repair, the research of available and effective treatments for
osteoarthritis (OA) represents a major challenge for clinicians. To this
regard, the use of bone marrow concentrate (BMC), containing different
cell populations including Mesenchymal Stromal Cells (MSCs) sur-
rounded by their microenvironment with a cocktail of multiple growth
factors, could represent a novel therapeutic approach for OA manage-
ment. This methodology allows to perform a one -step procedure
through a density gradient centrifugation of autologous bone marrow
avoiding all the problems related to cell manipulation. Most recent
studies demonstrated beneﬁts of the use of BMC for osteochondral
reconstruction in critical-sized defects.The purpose of this study was,
therefore, to assess the efﬁcacy of the use of BMC seeded onto a hya-
luronan scaffold compared to the use of expanded isolated MSCs in a
sheep model of OA.
Methods: Skeletally mature female Merino sheep were used for this
study.The induction of OAwas done surgically through unilateral partial
medial meniscectomy (MMX) to achieve amild grade of OA at 12weeks.
Treatment approaches consisted of autologous BMC and/or MSC seeded
onto Hyaff-11 from bone marrow and transplanted into the knee joint;
no treatment (OA group) and empty Hyaff-11 were used as controls.
Cartilage from femoral condyle and tibial plateau, synovial membranes
and medial menisci were assessed by macroscopic and histological
analysis supplemented by speciﬁc scoring systems. Protein expression
of various ﬁbrous, cartilaginous, catabolic, hypertrophic and inﬂam-
matory markers were examined by immunohistochemistry. All the
assessments were carried out 3 months after implantation. Data were
reported using 95% conﬁdence of interval of the mean and/or mean
with standard deviation.
Results: A mild grade of OA was developed after MMX at 12 weeks. A
series of OA changes, including cartilage loss, cell clones, hypertrophic
processes, subchondral bone thickness, osteophytes, hyperplasia of
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OA group. Hyaluronan scaffold displayed only a minor role in favoring
the wound-healing processes in the cartilage, synovial membrane and
menisci. There were instead a general beneﬁcial effect on these tissues,
when this scaffold was implanted with BMC and/or MSC. Macroscopic,
histological and immunohistochemical assessments clearly showed in
detail in BMC group an enhancement of cartilage repair in terms of a
down-regulation of some ﬁbrous, catabolic, hypertrophic and inﬂam-
matory markers particularly in medial femoral condyle respect OA
group (P<0.05). Moreover, the use of BMC determined an improvement
of various histological aspects in synovial membrane and menisci
reducing the ﬁbrous and inﬂammatory states respect OA group. MSC
group displayed a positive contribution particularly on medial femoral
condyle and low effect in tibial plateau due to the biomechanics of the
articular joint in sheep.
Conclusions: The sheep was chosen for this work because of its sim-
ilarities with humans, which render it an useful model. The ﬁndings
obtained in this study would support the use of BMC in clinical practice
for OAmanagement, as useful therapeutic tool, leading to a reduction of
the degenerative and inﬂammatory processes in cartilage, synovial
membrane and menisci during OA setting. Moreover, the clinical
application of BMC in OA management is attractive because it would
allow a one- step procedure, avoiding all the complications related to in
vitro cell manipulation, thus complying with US Food and Drug Asso-
ciation (FDA) restrictions.
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ALTERATIONS OF THE SUBCHONDRAL BONE INDUCED BY PTH [1-34]
PROVOKE EARLY OSTEOARTHRITIS IN VIVO
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Purpose: Systemic application of the 1-34 amino acid segment of the
parathyroid hormone (PTH [1-34]) stimulates bone formation, enhan-
ces diaphyseal fracture healing, and is approved for the clinical treat-
ment of postmenopausal osteoporosis. However, the effect of PTH [1-
34] on the subchondral bone is poorly understood. Here, we tested the
hypothesis that subcutaneous application of PTH [1-34] over 6 weeks
induces changes in the microarchitecture of the subchondral bone that
reciprocally affect the integrity of the articular cartilage within a naïve
osteochondral unit in vivo.
Methods: Daily subcutaneous injections of 10 mg PTH [1-34] per kg
body weight were given to the treatment group (n ¼ 4 adult female
Chinchilla bastard rabbits) for 6 weeks, controls received saline. The
animals were allowed full weight bearing and were fed a standard diet.
Blood samples were continuously collected to monitor renal function.
After sacriﬁce, the subchondral bone plate and subarticular spongiosa of
the femoral heads (n ¼ 16) were separately assessed by micro-com-
puted tomography. Osteoarthritic changes of the articular cartilage
were evaluated by macroscopic assessment and histological grading of
safranin orange/fast green stained sections, by polarized light micro-
scopy, and by computerized assessment of the mean immunostaining
intensities for type-I, type-II, and type-X collagen (Acris, Hiddenhausen,
Germany). Absolute and relative extents of hyaline and calciﬁed artic-
ular cartilage layers were determined histomorphometrically in a
standardized fashion on Goldner’s trichrome stained sections. The
effect of PTH [1-34] on apoptosis and PTH receptor (PTH1R) expression
of osteocytes and chondrocytes was determined by immunostaining,
applying a polyclonal caspase-3 (Cell Signaling Technology, Frankfurt,
Germany) and a monoclonal mouse PTH1R antibody (Abcam, Cam-
bridge, UK), respectively. Statistical comparison was conducted using a
linear model with generalized estimating equations. The Pearson cor-
relation coefﬁcient was applied to determine the strength of association
between PTH-induced key changes in subchondral bone and articular
cartilage. Data are given as mean  standard deviation. Two-tailed
values of p < 0.05 were considered signiﬁcant.
Results: PTH [1-34] enhanced bone volume (BV/TV; 45.58 3.69 versus
40.12  3.35%; p ¼ 0.010), mineral density (BMD; 1,062.48  104.16
versus 931.59  60.94 mg calcium hydroxyapatite/cm3; p ¼ 0.017), and
trabecular thickness (Tb.Th; 0.14  0.01 versus 0.13  0.01 mm; p ¼0.042) within the subarticular spongiosa, without affecting the sub-
chondral bone plate. Besides, PTH [1-34] signiﬁcantly increased the
thickness of the calciﬁed cartilage layer (285.32  46.17 versus 163.45
31.30 mm; p¼ 0.001). Moreover, PTH [1-34] also increased degeneration
of the articular cartilage (4.28 1.47 versus 1.97  0.46 overall score
points; p ¼ 0.040), reﬂected by cartilage surface irregularities (1.11 
0.96 versus 0.25  0.59; p < 0.001) and reduced matrix staining (2.75 
1.65 versus 1.68  0.55; p ¼ 0.029). Importantly, statistical analysis
revealed that such early osteoarthritic changes of the articular cartilage
correlate with (r ¼ 0.56) and are ascribed to the increased thickness of
the calciﬁed cartilage layer (p ¼ 0.026) and the enhanced mineral
density of the subarticular spongiosa (p ¼ 0.001). Systemic admin-
istration of PTH [1-34] neither affected the rate of apoptotic osteocytes
and chondrocytes within the osteochondral unit nor induced renal
failure, as serum levels of creatinine, phosphate, and urea nitrogen
remained constant over the observation period and were similar
between treatment and control group (p > 0.05 for all time points). The
macroscopic aspect of the articular cartilage, type-I, type-II, type-X
collagen content and distribution, and PTH1R expression remained
unaffected (all p > 0.05).
Conclusions: These ﬁndings identify a mechanism by which systemic
PTH [1-34] may provoke early osteoarthritis of the hyaline articular
cartilage by inducing microarchitectural modiﬁcations of the sub-
articular spongiosa and broadening of the calciﬁed cartilage layer.
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SENSITIZATION AND PAIN OVER TWO YEARS: THE MULTICENTER
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Purpose: Peripheral and central sensitization is associated with knee
pain severity in knee osteoarthritis (OA). Whether sensitization occurs
prior to or only concurrently with development of OA pain is not known
as prior studies have only been cross-sectional. Such insights would
have implications for understanding whether sensitization may be an
inherent trait vs. an induced state. We report here the ﬁrst longitudinal
evaluation of the effect of sensitization and its change over two years to
the incidence of knee pain and clinically meaningful change in pain
severity.
Methods: The Multicenter Osteoarthritis (MOST) Study is a NIH-funded
longitudinal cohort of persons with or at risk of knee OA. Subjects had
x-rays and WOMAC pain severity obtained at each study visit, and a
standardized somatosensory evaluation of mechanical temporal sum-
mation and pressure pain thresholds (PPT) at the wrist and patella at
60- and 84-months. Temporal summation was deﬁned by increased
pain during repeated mechanical stimulation (1 Hz x 30-sec) with a 60g
monoﬁlament. PPT was assessed with an algometer (1cm2 tip, 0.5 Kg/
sec) as the point at which the subject felt the pressure change to slight
pain. The average of 3 PPT trials was categorized into sex-speciﬁc ter-
tiles. Lower PPT indicates more sensitivity. Incident consistent frequent
knee pain (CFKP, pain on most days of the past 30 days on both a tel-
ephone screen and clinic visit) at the 84-month visit was determined
from among knees that did not have CFKP at the 60-month visit. Inci-
dent symptomatic knee OA (SxOA) at the 84-mo visit was deﬁned as
radiographic knee OA (ROA, KL grade 2) plus CFKP, assessed among
knees free of pain at the 60-mo visit with or without ROA. We used the
minimal clinically important difference (MCID) in WOMAC pain to
examine sensitization effects on clinically meaningful changes in pain
severity. We examined the relation of the baseline and 2-year changes
in somatosensory tests to each of these pain outcomes using logistic
regression with GEE. All analyses were adjusted for potential con-
founders (see Table for list).
Results: A total of 2308 subjects met eligibility criteria for these anal-
yses (mean age 67.6, mean BMI 30.9, 61% female). Neither temporal
summation nor PPT were associated with incident CFKP or incident
SxOA (ORs 0.7-1.2, all p>0.05). Baseline temporal summation at the
wrist was associated with a trend towards increased risk of MCID in
WOMAC pain worsening at follow-up, but baseline PPT was not asso-
ciated (Table). However, a decrease in PPT (:sensitivity) over 2 years
